Safe and Effective Delivery of Antitumor Drug Using Mesenchymal Stem Cells Impregnated with Submicron Carriers

Alexander S. Timin, Oleksii O. Peltek, Mikhail V. Zyuzin, Albert R. Muslimov, Timofey E. Karpov, Olga S. Epifanovskaya, Alena I. Shakirova, Mikhail V. Zhukov, Yana V. Tarakanchikova, Kirill V. Lepik, Vladislav S. Sergeev, Gleb B. Sukhorukov, Boris V. Afanasyev

Research output: Contribution to journalArticle

Abstract

An important area in modern malignant tumor therapy is the optimization of antitumor drugs pharmacokinetics. The use of some antitumor drugs is limited in clinical practice due to their high toxicity. Therefore, the strategy for optimizing the drug pharmacokinetics focuses on the generation of high local concentrations of these drugs in the tumor area with minimal systemic and tissue-specific toxicity. This can be achieved by encapsulation of highly toxic antitumor drug (vincristine (VCR) that is 20-50 times more toxic than widely used the antitumor drug doxorubicin) into nano- and microcarriers with their further association into therapeutically relevant cells that possess the ability to migrate to sites of tumor. Here, we fundamentally examine the effect of drug carrier size on the behavior of human mesenchymal stem cells (hMSCs), including internalization efficiency, cytotoxicity, cell movement, to optimize the conditions for the development of carrier-hMSCs drug delivery platform. Using the malignant tumors derived from patients, we evaluated the capability of hMSCs associated with VCR-loaded carriers to target tumors using a three-dimensional spheroid model in collagen gel. Compared to free VCR, the developed hMSC-based drug delivery platform showed enhanced antitumor activity regarding those tumors that express CXCL12 (stromal cell-derived factor-1 (SDF-1)) gene, inducing directed migration of hMSCs via CXCL12 (SDF-1)/CXCR4 pathway. These results show that the combination of encapsulated antitumor drugs and hMSCs, which possess the properties of active migration into tumors, is therapeutically beneficial and demonstrated high efficiency and low systematic toxicity, revealing novel strategies for chemotherapy in the future.

Original languageEnglish
Pages (from-to)13091-13104
Number of pages14
JournalACS Applied Materials and Interfaces
Volume11
Issue number14
DOIs
Publication statusPublished - 10 Apr 2019

Fingerprint

Stem cells
Antineoplastic Agents
Tumors
Vincristine
Toxicity
Chemokine CXCL12
Pharmacokinetics
Poisons
Drug delivery
Drug Carriers
Chemotherapy
Cytotoxicity
Encapsulation
Collagen
Pharmaceutical Preparations
Doxorubicin
Gels
Genes
Cells
Tissue

Keywords

  • human mesenchymal stem cells
  • malignant tumor
  • silica capsules
  • spontaneous and directed migration
  • tumor spheroid
  • tumor therapy
  • vincristine

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

Timin, A. S., Peltek, O. O., Zyuzin, M. V., Muslimov, A. R., Karpov, T. E., Epifanovskaya, O. S., ... Afanasyev, B. V. (2019). Safe and Effective Delivery of Antitumor Drug Using Mesenchymal Stem Cells Impregnated with Submicron Carriers. ACS Applied Materials and Interfaces, 11(14), 13091-13104. https://doi.org/10.1021/acsami.8b22685

Safe and Effective Delivery of Antitumor Drug Using Mesenchymal Stem Cells Impregnated with Submicron Carriers. / Timin, Alexander S.; Peltek, Oleksii O.; Zyuzin, Mikhail V.; Muslimov, Albert R.; Karpov, Timofey E.; Epifanovskaya, Olga S.; Shakirova, Alena I.; Zhukov, Mikhail V.; Tarakanchikova, Yana V.; Lepik, Kirill V.; Sergeev, Vladislav S.; Sukhorukov, Gleb B.; Afanasyev, Boris V.

In: ACS Applied Materials and Interfaces, Vol. 11, No. 14, 10.04.2019, p. 13091-13104.

Research output: Contribution to journalArticle

Timin, AS, Peltek, OO, Zyuzin, MV, Muslimov, AR, Karpov, TE, Epifanovskaya, OS, Shakirova, AI, Zhukov, MV, Tarakanchikova, YV, Lepik, KV, Sergeev, VS, Sukhorukov, GB & Afanasyev, BV 2019, 'Safe and Effective Delivery of Antitumor Drug Using Mesenchymal Stem Cells Impregnated with Submicron Carriers', ACS Applied Materials and Interfaces, vol. 11, no. 14, pp. 13091-13104. https://doi.org/10.1021/acsami.8b22685
Timin, Alexander S. ; Peltek, Oleksii O. ; Zyuzin, Mikhail V. ; Muslimov, Albert R. ; Karpov, Timofey E. ; Epifanovskaya, Olga S. ; Shakirova, Alena I. ; Zhukov, Mikhail V. ; Tarakanchikova, Yana V. ; Lepik, Kirill V. ; Sergeev, Vladislav S. ; Sukhorukov, Gleb B. ; Afanasyev, Boris V. / Safe and Effective Delivery of Antitumor Drug Using Mesenchymal Stem Cells Impregnated with Submicron Carriers. In: ACS Applied Materials and Interfaces. 2019 ; Vol. 11, No. 14. pp. 13091-13104.
@article{e8b0bd63a8c14dbdb8a42b3bdfeb7754,
title = "Safe and Effective Delivery of Antitumor Drug Using Mesenchymal Stem Cells Impregnated with Submicron Carriers",
abstract = "An important area in modern malignant tumor therapy is the optimization of antitumor drugs pharmacokinetics. The use of some antitumor drugs is limited in clinical practice due to their high toxicity. Therefore, the strategy for optimizing the drug pharmacokinetics focuses on the generation of high local concentrations of these drugs in the tumor area with minimal systemic and tissue-specific toxicity. This can be achieved by encapsulation of highly toxic antitumor drug (vincristine (VCR) that is 20-50 times more toxic than widely used the antitumor drug doxorubicin) into nano- and microcarriers with their further association into therapeutically relevant cells that possess the ability to migrate to sites of tumor. Here, we fundamentally examine the effect of drug carrier size on the behavior of human mesenchymal stem cells (hMSCs), including internalization efficiency, cytotoxicity, cell movement, to optimize the conditions for the development of carrier-hMSCs drug delivery platform. Using the malignant tumors derived from patients, we evaluated the capability of hMSCs associated with VCR-loaded carriers to target tumors using a three-dimensional spheroid model in collagen gel. Compared to free VCR, the developed hMSC-based drug delivery platform showed enhanced antitumor activity regarding those tumors that express CXCL12 (stromal cell-derived factor-1 (SDF-1)) gene, inducing directed migration of hMSCs via CXCL12 (SDF-1)/CXCR4 pathway. These results show that the combination of encapsulated antitumor drugs and hMSCs, which possess the properties of active migration into tumors, is therapeutically beneficial and demonstrated high efficiency and low systematic toxicity, revealing novel strategies for chemotherapy in the future.",
keywords = "human mesenchymal stem cells, malignant tumor, silica capsules, spontaneous and directed migration, tumor spheroid, tumor therapy, vincristine",
author = "Timin, {Alexander S.} and Peltek, {Oleksii O.} and Zyuzin, {Mikhail V.} and Muslimov, {Albert R.} and Karpov, {Timofey E.} and Epifanovskaya, {Olga S.} and Shakirova, {Alena I.} and Zhukov, {Mikhail V.} and Tarakanchikova, {Yana V.} and Lepik, {Kirill V.} and Sergeev, {Vladislav S.} and Sukhorukov, {Gleb B.} and Afanasyev, {Boris V.}",
year = "2019",
month = "4",
day = "10",
doi = "10.1021/acsami.8b22685",
language = "English",
volume = "11",
pages = "13091--13104",
journal = "ACS applied materials & interfaces",
issn = "1944-8244",
publisher = "American Chemical Society",
number = "14",

}

TY - JOUR

T1 - Safe and Effective Delivery of Antitumor Drug Using Mesenchymal Stem Cells Impregnated with Submicron Carriers

AU - Timin, Alexander S.

AU - Peltek, Oleksii O.

AU - Zyuzin, Mikhail V.

AU - Muslimov, Albert R.

AU - Karpov, Timofey E.

AU - Epifanovskaya, Olga S.

AU - Shakirova, Alena I.

AU - Zhukov, Mikhail V.

AU - Tarakanchikova, Yana V.

AU - Lepik, Kirill V.

AU - Sergeev, Vladislav S.

AU - Sukhorukov, Gleb B.

AU - Afanasyev, Boris V.

PY - 2019/4/10

Y1 - 2019/4/10

N2 - An important area in modern malignant tumor therapy is the optimization of antitumor drugs pharmacokinetics. The use of some antitumor drugs is limited in clinical practice due to their high toxicity. Therefore, the strategy for optimizing the drug pharmacokinetics focuses on the generation of high local concentrations of these drugs in the tumor area with minimal systemic and tissue-specific toxicity. This can be achieved by encapsulation of highly toxic antitumor drug (vincristine (VCR) that is 20-50 times more toxic than widely used the antitumor drug doxorubicin) into nano- and microcarriers with their further association into therapeutically relevant cells that possess the ability to migrate to sites of tumor. Here, we fundamentally examine the effect of drug carrier size on the behavior of human mesenchymal stem cells (hMSCs), including internalization efficiency, cytotoxicity, cell movement, to optimize the conditions for the development of carrier-hMSCs drug delivery platform. Using the malignant tumors derived from patients, we evaluated the capability of hMSCs associated with VCR-loaded carriers to target tumors using a three-dimensional spheroid model in collagen gel. Compared to free VCR, the developed hMSC-based drug delivery platform showed enhanced antitumor activity regarding those tumors that express CXCL12 (stromal cell-derived factor-1 (SDF-1)) gene, inducing directed migration of hMSCs via CXCL12 (SDF-1)/CXCR4 pathway. These results show that the combination of encapsulated antitumor drugs and hMSCs, which possess the properties of active migration into tumors, is therapeutically beneficial and demonstrated high efficiency and low systematic toxicity, revealing novel strategies for chemotherapy in the future.

AB - An important area in modern malignant tumor therapy is the optimization of antitumor drugs pharmacokinetics. The use of some antitumor drugs is limited in clinical practice due to their high toxicity. Therefore, the strategy for optimizing the drug pharmacokinetics focuses on the generation of high local concentrations of these drugs in the tumor area with minimal systemic and tissue-specific toxicity. This can be achieved by encapsulation of highly toxic antitumor drug (vincristine (VCR) that is 20-50 times more toxic than widely used the antitumor drug doxorubicin) into nano- and microcarriers with their further association into therapeutically relevant cells that possess the ability to migrate to sites of tumor. Here, we fundamentally examine the effect of drug carrier size on the behavior of human mesenchymal stem cells (hMSCs), including internalization efficiency, cytotoxicity, cell movement, to optimize the conditions for the development of carrier-hMSCs drug delivery platform. Using the malignant tumors derived from patients, we evaluated the capability of hMSCs associated with VCR-loaded carriers to target tumors using a three-dimensional spheroid model in collagen gel. Compared to free VCR, the developed hMSC-based drug delivery platform showed enhanced antitumor activity regarding those tumors that express CXCL12 (stromal cell-derived factor-1 (SDF-1)) gene, inducing directed migration of hMSCs via CXCL12 (SDF-1)/CXCR4 pathway. These results show that the combination of encapsulated antitumor drugs and hMSCs, which possess the properties of active migration into tumors, is therapeutically beneficial and demonstrated high efficiency and low systematic toxicity, revealing novel strategies for chemotherapy in the future.

KW - human mesenchymal stem cells

KW - malignant tumor

KW - silica capsules

KW - spontaneous and directed migration

KW - tumor spheroid

KW - tumor therapy

KW - vincristine

UR - http://www.scopus.com/inward/record.url?scp=85064190041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064190041&partnerID=8YFLogxK

U2 - 10.1021/acsami.8b22685

DO - 10.1021/acsami.8b22685

M3 - Article

VL - 11

SP - 13091

EP - 13104

JO - ACS applied materials & interfaces

JF - ACS applied materials & interfaces

SN - 1944-8244

IS - 14

ER -